Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas

Table 1 Characteristics of the patients with lymphoepitelioma-like hepatic carcinomas n (%)

	LEL-HCC (n = 29)	LEL-ICC (n = 24)
Age at diagnosis, median (range)	61 (39-79)	53 (19-71)
HBV infection (positive)	3	7
HCV infection (positive)	16	2
EBV infection (positive)	3	17
Cirrhosis	13	6
Maximum diameter of the tumor (mm)	25 (13-130)	45 (16-160)
Surgical treatment (OLT/resection)	6/23	0/24
Rate of recurrence	6 (20.6)	8 (36.3)

LEL-HCC: Lymphoepithelioma-like hepatocellular carcinomas; LEL-ICC: Lymphoepithelioma-like cholangiocarcinomas; EBV: Epstein-Barr virus; OLT: Orthotopic liver transplantation; HCV: Hepatitis C virus; HBV: Hepatitis B virus.

Table 2 Pathological findings in patients with lymphoepithelioma-like-hepatic carcinomas

		LEL-HCC (n = 29)	LEL-ICC (n = 24)
Histological features
	Poorly differentiated	16/29	10/24
	Moderately differentiated	13/29	3/24
	Combined LEL-HCC and HCC	None
	Combined LEL-ICC and ICC		9/24
Immunohistology
	HepPAR1	3/3	1/2
	CK7 and CK19	4/11	24/24
	EpCAM	ND	7/7
	CD133	ND	7/7
EBV status
	EBERs	3/18	17/24
	LMP1/2 antigens	ND	0/8
	LMP1 gene	ND	2/2
	EBNA2	ND	1/1
Lymphoid infiltration
	CD3/CD20 ratio > 1	29/29	4/4
	CD4/CD8 ratio < 1	11/29	1/4

LEL-HCC: Lymphoepithelioma-like hepatocellular carcinomas; LEL-ICC: Lymphoepithelioma-like cholangiocarcinomas; EBV: Epstein-Barr virus; EBERs: EBV-encoded RNAs; LMP: Latent membrane protein; EBNA2: Epstein Barr nuclear antigen 2; ND: Not done.